Astellas Institute for Regenerative Medicine clinical trials
Acquired by Astellas Pharma Inc, Feb 10, 2016 · source ↗
The registry lists 10 studies whose lead sponsor is Astellas Institute for Regenerative Medicine. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 28, 2026.
Before and after it joined Astellas Pharma Inc
- First submitted before Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- 6
- First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- 4
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Astellas Institute for Regenerative Medicine10 studies
Something wrong with this grouping? Tell us on the Astellas Pharma Inc page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Astellas Pharma Inc studies →
- A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye ConditionsRecruitingNCT07734064Phase 1
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationRecruitingNCT03178149Phase 1
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell TherapyEnrolling by invitationNCT03167203Phase 1/2
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMDCompletedNCT02463344
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted before Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy PatientsCompletedNCT02445612
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted before Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular DystrophyCompletedNCT01345006Phase 1/2
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted before Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)CompletedNCT01469832Phase 1/2
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted before Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular DegenerationCompletedNCT01344993Phase 1/2
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted before Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)CompletedNCT02941991
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc
- Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMDWithdrawnNCT02563782Phase 2
Sponsor listed in the registry: Astellas Institute for Regenerative Medicine · First submitted before Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc